Determination of Remifentanil's ED50 for Rapid Sequence Intubation Avoiding Bradycardia and Hypotension in Adults

NCT ID: NCT03065309

Last Updated: 2017-09-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-25

Study Completion Date

2017-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will find the median effective dose of remifentanil for rapid sequence intubation which avoids bradycardia and hypotension

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Remifentanil is becoming popular for rapid sequence intubation because it has a fast onset and ultra-short half-life.

Remifentanil a potent opioid associated to bradycardia and hypotension at high doses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bradycardia Hypotension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Intervention Model

SEQUENTIAL

Adaptative clinical trial, Dixon's Up-And-Down Method
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Participant will receive propofol before induction

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single Arm

Patients will receive bolus dose of remifentanil before intubation

Group Type EXPERIMENTAL

Remifentanil

Intervention Type DRUG

bolus dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Remifentanil

bolus dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Indication of anesthesia induction

Exclusion Criteria

* Protocol violation
* Monitoring problems
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Brasilia University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gabriel Magalhaes Nunes Guimaraes

Head of Anesthesia department

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gabriel MN Guimarães, MSc

Role: STUDY_DIRECTOR

Head of Anesthesiology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital das Forças Armadas

Brasília, Federal District, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TCC-Lara-2017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Reduction of Remifentanil-related Complications
NCT01003028 NOT_YET_RECRUITING PHASE4